FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 58403

News■ Unclear/unknown

Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

EXHIBIT · mmx.prnewswire.com
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-30 20:30 UTC
LAST UPDATE2026-09-30 20:30 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

Diagnostic data may support test adoption, but no revenue or approval figures are given.

Melanoma test data supports clinical use
CATALYST TO WATCH

Guideline inclusion or reimbursement decisions

MAIN RISK

Data may not change clinical practice

FULL DISPATCH

Data show patients with low-risk DecisionDx-Melanoma i31-SLNB results had sentinel lymph node (SLN) positivity below 5% when biopsied, and eligible patients who avoided SLNB had five-year recurrence-free survival (RFS) of 99.6% Separate ePoster shows DecisionDx-Melanoma identifies...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01prnewswireprnewswire.com · PRIMARY2026-09-30 20:30 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

←CORRELATIONshares Healthcare
Merger Dominoes Fall as HealthPartners and Essentia Combine
2026-09-30 14:11 UTC
←CORRELATIONshares Healthcare
Signed and Scrubbed: September 2026 hospital M&A
2026-09-30 14:58 UTC
←CORRELATIONshares Healthcare
Midmark RTLS expands Epic Toolbox presence with CareFlow RTLS Staff Duress
2026-09-30 18:17 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.